Organovo (ONVO)
(Delayed Data from NSDQ)
$0.47 USD
+0.01 (2.46%)
Updated Oct 18, 2024 03:59 PM ET
After-Market: $0.47 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.47 USD
+0.01 (2.46%)
Updated Oct 18, 2024 03:59 PM ET
After-Market: $0.47 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Will Organovo Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Organovo.
Zacks.com featured highlights include: Avinger, Alexion Pharmaceuticals, CyberArk Software, Organovo and Qualys
by Zacks Equity Research
Zacks.com featured highlights include: Avinger, Alexion Pharmaceuticals, CyberArk Software, Organovo and Qualys
What Bargain Hunting? Tap 5 Stocks With Rising P/E
by Sanghamitra Saha
Bet on these top-ranked stocks with rising P/E for outsized gains.
Organovo (ONVO) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
Organovo (ONVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Organovo (ONVO) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Organovo (ONVO) delivered earnings and revenue surprises of 0.00% and -13.13%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Organovo (ONVO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Organovo (ONVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Options Traders Expect Huge Moves in Organovo (ONVO) Stock
by Zacks Equity Research
Organovo (ONVO) needs investors to pay close attention to the stock based on moves in the options market lately.
Organovo (ONVO) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Organovo (ONVO) delivered earnings and revenue surprises of 14.29% and -10.15%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Will Organovo (ONVO) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Organovo (ONVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Buy Stocks for December 14th
by Nitish Marwah
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
Organovo (ONVO) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Organovo (ONVO) delivered earnings and revenue surprises of 37.50% and 4.43%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Organovo (ONVO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Organovo (ONVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Organovo (ONVO) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Organovo (ONVO) delivered earnings and revenue surprises of 0.00% and -40.66%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
5 Top Performing Stocks of the Best ETF of May
by Sweta Killa
Inside the best performing stocks of the top ETF of May - ARKG.
Can The Uptrend Continue for Organovo Holdings (ONVO)?
by Zacks Equity Research
Investors certainly have to be happy with Organovo Holdings, Inc. (ONVO) and its short term performance
Zacks.com highlights: BioTime, Ritter Pharmaceuticals, Organovo Holdings, American Superconductor and Stratasys
by Zacks Equity Research
Zacks.com highlights: BioTime, Ritter Pharmaceuticals, Organovo Holdings, American Superconductor and Stratasys
Try Rising P/E Investing With 5 Top-Ranked Stocks
by Zacks Equity Research
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.
Zacks.com highlights: BioTime, Ritter Pharmaceuticals, Organovo Holdings, Signal Genetics and Stratasys
by Zacks Equity Research
Zacks.com highlights: BioTime, Ritter Pharmaceuticals, Organovo Holdings, Signal Genetics and Stratasys
Keep Faith in Rising P/E: Play 5 Top-Ranked Stocks
by Zacks Equity Research
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.
Zacks.com featured highlights: Fortuna Silver Mines, Ritter Pharmaceuticals , Organovo Holdings, Western Digital and Willdan Group
by Zacks Equity Research
Zacks.com featured highlights: Fortuna Silver Mines, Ritter Pharmaceuticals , Organovo Holdings, Western Digital and Willdan Group
Take the Less-Trodden Path: Rising P/E for 5 Winning Stocks
by Zacks Equity Research
Cross the age-old barrier of low P/E investing, bet on these five stocks that boast a rising P/E.
The Zacks Analyst Blog Highlights: Codexis, EMCORE, Intevac, Organovo Holdings and StarTek
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Codexis, EMCORE, Intevac, Organovo Holdings and StarTek